The Joint Corp. has reacquired regional developer rights in Texas, including major cities like Dallas, Austin, San Antonio, and Houston, enhancing its ability to support franchisees and expand clinics. This move is part of a broader 2026 strategy where The Joint also reacquired territories in Chicago, Minnesota, Ohio, Iowa, and Nebraska, opening opportunities for over 150 new clinics. The strategy aims to strengthen clinic operations, attract quality franchisees, and accelerate growth as The Joint transitions to a pure-play franchisor model. The company plans further reacquisitions to expand its national footprint and improve access to chiropractic care.
The Joint Chiropractic expansion news is presented with Pluang's health sector data as context. For readers following health stocks, here is Pluang's market snapshot as of Oct 06, 2026 23:41 WIB: Out of 100 health-sector US stocks, 36 rose and 62 fell. Notable movers include DNA at USD 12.51 (-16.52%), TWST at USD 173.01 (-15.60%), and TXG at USD 82.95 (-15.13%). Typical hold times range from 8 to 93 days, with varying buy/sell ratios.
Constellation Brands reported earnings per share of $3.74, surpassing analyst estimates of $3.55, and revenue of $2.63 billion, exceeding the $2.54 billion forecast. The company saw a 5% increase in beer sales and a 17% rise in wine and spirits sales...
Tilray Brands will announce its fiscal Q1 2027 earnings on October 8, with analysts forecasting a loss of $0.16-$0.19 per share on revenues around $265-$268 million, marking about 26% growth from last year. Investors will focus on cannabis and bevera...
On October 6, 2026, five notable stocks surged between 20.9% and 52.7%, driven by various positive developments. Apimeds Pharmaceuticals rose 52.7% after its subsidiary signed a blockchain contract, while Option Care Health gained 32.7% following a $...
On October 6, five notable stocks saw significant declines, with losses ranging from 17.5% to 50.1%. ArriVent BioPharma's shares plunged 46.9% after its lung cancer treatment failed to meet the primary endpoint in a Phase 3 trial. Armada Acquisition ...
Evercore ISI raised its price target for Marvell Technology to $433 from $275, maintaining an Outperform rating. This follows Marvell's optimistic revenue projections, expecting $20 billion by fiscal 2028 and $70-$90 billion by fiscal 2031, driven by...
